MedTrace Logo

Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma

NCT03610685 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-03-06

No results posted yet for this study

Summary

The aim of the project is to study the persistence of inflammation after addition of an interleukin-5 (IL-5) blocker in severe eosinophilic asthma as a study of untreated pathways in these patients.

Conditions

Interventions

DRUG

Prednisolone

Given daily for 2 weeks

DRUG

Placebo oral capsule

Given daily for 2 weeks

Sponsors & Collaborators

  • Queen's University, Belfast

    collaborator OTHER

  • NHS Greater Glasgow and Clyde

    lead OTHER

Principal Investigators

  • Rekha Chaudhuri, MD · NHS Greater Glasgow and Clyde

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-19
Primary Completion
2020-01-07
Completion
2020-01-07
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03610685 on ClinicalTrials.gov